New Research Sheds Light on the Initial Stages of Brain Cancer Development

Recent research has identified processes that could lead to the growth of tumors. The research was conducted by a team at the University of Plymouth’s Brain Tumour Research Centre, led by Dr. Claudia Barros.

This institution is focused on providing new understanding of certain groups of common, low-grade brain tumors. For their research, the investigators used Drosophila fruit flies. This allowed them to identify changes that could play a role in a healthy cell becoming a cancerous one in the brain.

Once this was done, investigators translated their discovery using glioma cells. Glioma is a tumor commonly found in the brain. Estimates show that roughly 33% of brain tumors are gliomas, which arise from the glial cells.

The findings allowed researchers to observe a mechanism that involved the HEATR1 protein work with the MYC growth regulator to increase ribosome production. Ribosomes are needed in tumor cells to facilitate growth and cell division. Overexpression of the HEATR1 protein has also been linked to poor prognosis in some tumors.

Barros explained that the Drosophila fruit fly allowed the company to pinpoint and assess cells at the first stages of brain tumor development. In their report, the investigators stated that more work was required to better understand how these changes affected cells in the body. They explained that preventing or slowing the growth of tumors was essential in improving rates of survival for patients as well as their quality of lives.

This study contributes to understanding of how tumors in the brain develop and opens new avenues of study to find new drug targets for gliomas.

Dr. Karen Noble, director of research, policy and innovation at the institution, stated that these findings were significant because they could aid in the development of new therapies that could target tumor cells more effectively and in turn, improve patient outcomes.

This research is part of ongoing studies being conducted at the institution and will allow researchers to better understand both high and low-grade brain tumors.

The study’s findings were published in “EMBO Reports.”

Other researchers involved in the study included Laura R Diaz, Karolina J Jaworek, Jon Gil-Ranedo, Joao Pinheiro Marques, NsikanNsek, David A Hilton, Eleni Costa, Oliver Warrington, C Oliver Hanemann, Torsten Bossing, Hubert Bieluczyk and Matthias E Futschik.

This research was sponsored by the Peninsula Medical School, University of Plymouth; Tenovus Cancer Care; Brain Research UK; and Fundação para a Ciência e Tecnologia (FCT).

As more becomes known about how brain tumors develop, treatments of the future from entities such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are likely to be more efficacious in stopping the growth of these malignancies since the formulations will be designed to disrupt the mechanisms powering cancer’s proliferation.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

San Francisco, CA
415.949.5050 Office

BioMedWire is powered by IBN


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050